Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
ALLISON GATLIN

Ascendis Reverses Its Losses After A Key Drug Misses Sales Forecasts

Biotech stock Ascendis Pharma reversed a plunge Thursday after its growth hormone deficiency treatment, Skytrofa, missed first-quarter sales estimates.

The Food and Drug Administration approved Skytrofa for children with insufficient growth hormone last August. But many patients apparently continue to receive free treatment, SVB Securities analyst Joseph Schwartz said in a report to clients. As a result, Skytrofa sales were just 1.9 million euros — roughly $2 million. Wall Street had predicted roughly double that.

"Based on prescription growth quarter over quarter, we believe that sales should come through once patients are converted over to commercial therapy," he said. "However, the timing remains unclear and we are lowering our sales estimates as a result."

But after falling as much as 21%, the biotech stock pared its losses and gained 2.5% to close at 80.01 on today's stock market.

Biotech Stock: Revenue Beats, Losses Widen

Overall, the first quarter ended up mixed. Total revenue came in at 6.8 million euros — about $7.1 million — and easily topped forecasts, according to FactSet. But Ascendis had a wider-than-expected loss that also grew year over year.

Still, SVB's Schwartz noted Skytrofa uptake is so far encouraging. As of March 31, 349 physicians have prescribed the weekly injection 978 times.

"While it appears that Ascendis is doing a good job of converting the pediatric market to Skytrofa (from daily growth hormone), it appears that converting them to commercial therapy is taking some more time based on reported sales," he said.

It appears Ascendis is willing to sacrifice near-term sales to gain share as it competes with big names like Novo Nordisk, Schwartz said.

Schwartz kept his outperform rating on the biotech stock. He has a 174 price target on Ascendis stock.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.